Literature DB >> 8290387

Mortality trend from prostate cancer in The Netherlands (1950-1989).

J W van der Gulden1, L A Kiemeney, A L Verbeek, H Straatman.   

Abstract

The trend in prostate cancer mortality in The Netherlands was studied, using data from the National Causes of Death Registry of the Central Bureau of Statistics. During the period 1950-1989, the age-adjusted mortality rate showed a steady rise from 20.5 to 30.6 per 100,000 man-years. A multiplicative model was used to examine possible period effects and birth-cohort effects separately. This analysis demonstrated that the increase in prostate cancer mortality is largely due to a birth-cohort effect, though calendar time of death may have had a slight effect as well. Among Dutch men, a continuous increase of mortality from prostate cancer was found in consecutive birth cohorts. This finding is in contrast with that of comparable studies in other Western countries, in which a peak mortality rate was found for the cohort born at the end of the 19th century with stabilizing or declining rates for later birth cohorts.

Entities:  

Mesh:

Year:  1994        PMID: 8290387     DOI: 10.1002/pros.2990240108

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  3 in total

Review 1.  Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate.

Authors:  M A Noordzij; G J van Steenbrugge; T H van der Kwast; F H Schröder
Journal:  Urol Res       Date:  1995

2.  Striking increase in incidence of prostate cancer in men aged < 60 years without improvement in prognosis.

Authors:  P N Post; D Stockton; T W Davies; J W Coebergh
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

3.  Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis.

Authors:  Aditi Gupta; Wei Cao; Meenakshi A Chellaiah
Journal:  Mol Cancer       Date:  2012-09-11       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.